Company intelligence / Profile preview

KALDUR Therapeutics

Ownership: Private
Development stage: Other

Overview

KALDUR Therapeutics is a team of clinical doctors and scientists with extensive backgrounds in medical research and innovation. The company is led by Dr. Hans Tómas Björnsson, MD, PhD, who is also a Professor of Translational Medicine and Pediatrics at the University of Iceland. The company's mission centers on developing new therapeutics through translational medicine approaches but specific clinical results or pipeline details are not publicly disclosed as of June 2025.

Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on KALDUR Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KALDUR Therapeutics.

Explore the full profile